The global landscape is fraught with simmering tensions, but one universal commonality remains intact: the need for a coronavirus vaccine.However, Canaccord analyst John Newman believes that until a vaccine becomes available, there could be another solution. And one just as potent.“Regeneron’s (REGN) REGN-COV2 antibody cocktail could provide immediate treatment for COVID-19 patients, whereas a vaccine would not. We believe REGN-COV2 is a much-needed approach to provide both immediate impact and a supplement to protection once vaccines are (hopefully) available,” said the 5-star analyst.Regeneron initiated the Phase 3 study for REGN-COV2 in July, evaluating its efficacy in treating and preventing COVID-19. …read more
Source:: Yahoo Finance
